Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors

A method of treating a subject having liver disease or at risk of having liver disease, having fatty liver disease or at risk of having fatty liver disease, having hepatocellular carcinoma or at risk of having hepatocellular carcinoma, having liver cirrhosis or at risk of having liver cirrhosis, having liver fibrosis or at risk of having liver fibrosis, and/or having simple steatosis, steatohepatitis, or non-alcoholic steatohepatitis (NASH) or at risk of having simple steatosis, steatohepatitis, or NASH, the method comprising administering a glycerol-3-phosphate acyltransferase (GPAM) inhibitor to the subject, wherein:

• the GPAM inhibitor comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to a GPAM mRNA;
• and
• the subject is heterozygous for a GPAM predicted loss-of-function variant mRNA molecule comprising SEQ ID NO:
• 10, SEQ ID NO:
• 11, SEQ ID NO:
• 12, SEQ ID NO:
• 13, and/or SEQ ID NO:
• 14.